0
0
Issue Details / Capital History
The firm is popping out with its maiden guide constructing route combo IPO value Rs. 1450 cr. (approx. of 20923521 fairness shares on the higher cap). The IPO consists of contemporary fairness shares value Rs. 500 cr. (approx. 7215007 fairness shares on the higher cap), and an Offer for Sale (OFS) value Rs. 950 cr. (approx. 13708514 fairness shares on the higher cap). The firm has introduced a worth band of Rs. 660 – Rs. 693 per fairness shares of Re. 1 every. The difficulty opens for subscription on October 21, 2026, and can shut on October 23, 2026. The minimal software to be made is for 21 shares and in multiples thereon, thereafter. Post allotment, shares shall be listed on BSE and NSE. The difficulty constitutes 19.34% of the post-IPO paid-up fairness capital. From the online proceeds of the contemporary fairness shares difficulty, the corporate will make the most of Rs. 320.90 cr. for compensation/prepayment of sure borrowings, Rs. 54.10 cr. for funding in its wholly owned subsidiary PMHPL for compensation/prepayment of its sure borrowings, and the remainder for common company functions.
The firm has allotted not lower than 75% for QIBs, no more than 15% for HNIs, and less than 10% for Retail buyers.
The joint Book Running Lead Managers (BRLMs) to this difficulty are JM Financial Ltd., BofA Securities India Ltd., Nuvama Wealth Management Ltd., whereas MUFG Intime India Pvt. Ltd. is the registrar to the problem. JM Financial Services Ltd., Nuvama Wealth Management Ltd. are the syndicate members.
Having issued preliminary fairness shares at par worth, the corporate has issued additional fairness shares within the worth vary of Rs. 3.50 – Rs. 237 per share (based mostly on Re. 1 FV), between February 2006, and April 2025. It has additionally issued bonus shares within the ratio of 1 for 1 in March 2024. The common price of acquisition of shares by the promoters/promoting stakeholders is Rs. 2.35, and Rs. 114.15 per share.
Post-IPO, its present paid-up fairness capital of Rs. 10.10 cr. (100986187 fairness shares) will stand enhanced to Rs. 10.82cr. (108201194 fairness shares) on the higher cap. Based on the higher band, the corporate is on the lookout for a market cap of Rs. 7498.34cr.
On the monetary efficiency entrance, for the final three fiscals, the corporate has (on a consolidated foundation) posted a complete earnings/web revenue/ – (loss), of Rs. 1151.02 cr. / Rs. – (15.33) cr. (FY24), Rs. 1314.21 cr. / Rs. – (57.98) cr. (FY25), and Rs. 1628.78 cr. / Rs. 43.83 cr. (FY26). ForQ1 of FY27 ended on June 30, 2026, it earned a web revenue of Rs. 49.68 cr. on a complete earnings of Rs. 478.45 cr. The firm posted development in its high strains for the reported durations, and reported turnaround from FY26 onwards. Rising commerce receivables year-on-year elevate concern. Its contingent liabilities stood at Rs. 398.44 cr. as of June 30, 2026. Its debt fairness ratio was at 3.21 as of June 30, 2026.
For the final three fiscals, the corporate has posted a mean EPS of Rs. – (0.07) and a mean RoNW of – (1.14) %. The difficulty is priced at a P/BV of 15.73 based mostly on its NAV of Rs. 44.06 as of June 30, 2026, and at a P/BV of 8.38 on the idea of post-IPO NAV of Rs. 82.71 per share on the higher cap.
If we attribute FY27 annualized earnings to its post-IPO absolutely diluted paid-up fairness capital, then the asking worth is at P/E of 37.72. Based on FY26 earnings, the P/E stands at 171.11. The difficulty seems absolutely priced based mostly on its latest common efficiency.
For the reported durations, the corporate has reported PAT Margins of – (1.33) % (FY24), – (4.41) % (FY25), 2.69% (FY26), 10.38% (Q1-FY27), and RoCE margins of 5.86%, 2.71%, 10.76%, 4.23%, respectively, for the referred durations.
Dividend Policy
The firm has not paid any dividends for the reported durations of the supply doc. It has adopted a dividend coverage in July 2024, based mostly on its earnings and future prospects.
Comparison with Listed Peers
As per the supply doc, the corporate has proven Aster DM, Apollo Hospitals, Fortis Healthcare, Global Health, Jupiter Lifeline, Krishna Institute, Manipal Health, Max Healthcare, Narayana Hrudayalaya, and Yatharth Hospital, as its listed friends. They are at present buying and selling at a P/E of 163.0, 53.7, 52.4, 58.2, 43.0, 138.0, 96.2, 55.0, 40.8, and 52.7 (as of October 16 2026). However, they don’t seem to be really comparable on an apple-to-apple foundation. This comparability seems to be an eyewash.
Paras Healthcare Ltd. (PHL) is a scientific specialty-led hospital platform offering tertiary and quaternary healthcare providers by means of a community of eight hospitals with an combination mattress capability of two,211 beds as of June 30, 2026 throughout North India, Bihar and Jharkhand. It operates beneath the “Paras Health” model, with a presence in 5 states and one union territory – Gurugram and Panchkula in Haryana; Patna and Darbhanga in Bihar; Kanpur in Uttar Pradesh; Udaipur in Rajasthan; Ranchi in Jharkhand; and Srinagar within the union territory of Jammu and Kashmir.
The firm has a dedicated pipeline for enlargement of community, with the deliberate addition of a hospital with a mattress capability of 300 beds in Gurugram and a hospital with a capability of 500 beds in Ludhiana, which it intends to launch by Fiscal 2027 and Fiscal 2028, respectively. The firm expects to extend complete mattress capability throughout hospitals to three,011 beds by March 31, 2028. Over its 20-year working historical past, it has developed specialty clusters inside its hospitals by means of investments in superior scientific infrastructure, expert medical expertise and standardized care protocols. Its hospitals are designed to ship high-acuity care and supply remedies throughout a broad spectrum of scientific specialties, with a deep deal with cardiac sciences, oncology sciences, neuro sciences, gastro sciences, orthopedics and sports activities damage, and renal sciences (collectively, “CONGOR”). These CONGOR specialties accounted for 74.35%, 75.30%, 74.70%, 71.92% and 72.34% of its income from operations within the three months interval ended June 30, 2026 and June 30, 2025, and Fiscals 2026, 2025 and 2024, respectively. As of June 30, 2026, it had 1,084 medical doctors and 1,937 nurses throughout its hospital community.
Over the three months interval ended June 30, 2026 and the final three Fiscals, on a consolidated foundation, PHL has demonstrated robust development pushed by a rise in affected person volumes throughout hospitals. Its income from operations has grown at a CAGR of 19.26% from Rs. 1129.04 cr. in Fiscal 2024 to Rs. 1605.95 cr. in Fiscal 2026, pushed by a rise in Occupied Bed Days and ARPOB at its Mature Hospitals, reflecting continued deal with high-acuity specialties and scientific packages. Its EBITDA has grown at a CAGR of 47.41% from Rs. 154.41 cr. in Fiscal 2024 to Rs. 335.58 cr. in Fiscal 2026, with EBITDA margins increasing as its Emerging Hospitals and New Hospitals have begun to ramp up, producing working leverage. Its income from operations elevated by 27.66% from Rs. 368.39 cr. within the three months interval ended June 30, 2025 to Rs. 470.28 cr. within the three months interval ended June 30, 2026, and its EBITDA elevated by 71.13% from Rs. 66.31 cr. within the three months interval ended June 30, 2025 to Rs. 113.48 cr. within the three months interval ended June 30, 2026.
It established its first hospital in Gurugram, Haryana in 2006 with 200 beds, making it the primary company hospital entrant amongst listed friends within the metropolis. (Source: CRISIL Report) Over the years, it has expanded hospital platform in a largely natural method, specializing in operationalizing and scaling hospitals by means of inner accruals and debt financing, with restricted fairness infusions. It has elevated its complete mattress capability from 2,135 beds as of March 31, 2024 to 2,211 beds as of June 30, 2026, and is among the largest healthcare suppliers in North India, Bihar and Jharkhand by way of mattress capability as of June 30, 2026. (Source: CRISIL Report).
It has persistently recognized underserved markets with massive catchment populations the place it believes there’s a want for high-quality tertiary and quaternary care, robust demand for healthcare providers, in addition to proximity to medical faculties to supply medical professionals; and have arrange hospitals in these places.
PHL’s eight hospitals are at completely different phases of operational maturity, which correlates to their occupancy ranges, margins and development trajectories. This balanced mixture of mature, rising and New Hospitals permits it to mix secure money technology with seen development headroom, and has supported consolidated margin enlargement over time as newer hospitals enhance their occupancy ranges.
The firm operates its hospitals by means of a mixture of owned, leased, revenue-sharing and public-private partnership fashions, and has adopted a calibrated strategy to capital deployment, evaluating capital-efficient buildings selectively based mostly on market traits, capital effectivity concerns and long-term working management. Its leased services are structured by means of fastened hire, income sharing or hybrid preparations comprising a partial fastened hire and a partial income share. Company’s development choices are guided by outlined return thresholds and the energy of its stability sheet.
PHL has progressively expanded its presence throughout North India, Bihar and Jharkhand, rising its mattress capability from 200 beds as of June 2006 to 2,211 beds as of June 30, 2026, whereas concurrently deepening specialty packages and enhancing working metrics as hospitals mature. The firm has deliberate a complete mattress capability of 3011 by the top of FY28. The ‘Paras Health’ model is well-recognized for its dedication to scientific excellence, accessibility and patient-centric care, as mirrored in its affected person satisfaction rating of 90.60 as of March 31, 2026, in addition to its web promoter rating of 93.31 as of the identical date. Together, these metrics exhibit constant affected person satisfaction throughout its hospital community. PHL’s deal with high quality is additional bolstered by seven of its eight hospitals being accredited by the NABH. Further, with impact from May 21, 2026, it has change into an government member of the Association of Healthcare Providers (India). It has additionally been just lately licensed as a ‘Great Place to Work’ in India, which displays its deal with fostering a constructive office tradition. As of June 30, 2026, it had a workforce of 5,315 professionals, together with 1,084 medical doctors, 1,937 nurses and a pair of,294 different personnel. Its medical doctors are engaged on a payroll foundation, on a full-time or part-time consultancy foundation.
Merchant Banker’s Track Record
The three BRLMs related to this difficulty have dealt with 83 public points up to now three fiscals, out of which 25 points closed under the supply worth on itemizing date.
Conclusion
PHL is a scientific specialty-led hospital platform offering tertiary and quaternary healthcare providers beneath its personal model “Paras Health”. Currently it operates with 2211 beds in its eight hospitals in Northern India, Bihar and Jharkhand. It has plans to extend its mattress capability to 3011 beds by FY28 finish. It has one hospital in Kashmir J & Ok Union Territory as properly. The firm has posted regular development in its high strains for the reported durations, and turned the nook from FY26 onwards. Based on its latest common monetary information, the problem seems absolutely priced. Well-informed buyers could park funds for long run.
Dilip Davda is a veteran monetary journalist related to the Indian inventory market since 1978. He has been contributing to print and digital media on capital markets, insurance coverage, and finance since 1985.
He is well known for reviewing public points and non-convertible debentures (NCDs) within the main market. Drawing on over three many years of market expertise and shut interplay with service provider bankers, his critiques deal with detailed basic and monetary evaluation of firms, with a particular emphasis on SME public points.
Disclaimer: No monetary data in any respect printed anyplace right here needs to be construed as a suggestion to purchase or promote securities, or as recommendation to take action in any method in any respect. All matter printed right here is solely for academic and knowledge functions solely and in no way needs to be used for making funding choices. Readers should seek the advice of a certified monetary advisor earlier than making any precise funding choices, based mostly on the knowledge printed right here. Any reader taking choices based mostly on any data printed right here does so solely at their very own threat. Investors ought to keep in mind that any funding in inventory markets is topic to unpredictable market-related dangers. The above data relies on RHP and different paperwork obtainable as of date coupled with market notion. The writer has no plans to speculate on this supply.
Source link
#Paras #Healthcare #IPO #Review #Dilip #Davda #IPO #Watch
